Search

Your search keyword '"Tomoo Ikari"' showing total 2 results
Start Over Author "Tomoo Ikari" Publisher elsevier
2 results on '"Tomoo Ikari"'

1. Multiple cavities with halo sign in a case of invasive pulmonary aspergillosis during therapy for drug-induced hypersensitivity syndrome

Author

Tomoo Ikari, Katsura Nagai, Masashi Ohe, Toshiyuki Harada, and Yasushi Akiyama

Subjects
Invasive pulmonary aspergillosis, Drug-induced hypersensitivity syndrome, Human herpes virus 6 (HHV-6), Chronic obstructive pulmonary disease (COPD), Halo sign, Diseases of the respiratory system, RC705-779
Abstract

A 67-year-old female with rheumatoid arthritis and asthma-chronic obstructive pulmonary disease overlap syndrome was admitted for drug-induced hypersensitivity syndrome (DIHS) caused by salazosulfapyridine. Human herpes virus 6 (HHV-6) variant B was strongly positive on peripheral blood. Multiple cavities with ground grass opacities rapidly emerged predominantly in the upper and middle lobes. She was diagnosed with invasive pulmonary aspergillosis (IPA), and was treated successfully with antifungal agents. Therapeutic systemic corticosteroids, emphysematous change in the lungs, and the worsening of the patient's general condition due to DIHS were considered major contributing factor leading to IPA. HHV-6 reactivation could have an effect on clinical course of IPA. Cavities with halo sign would provide an early clue to IPA in non-neutropenic and immunosuppressive patients.

Published
2017
Full Text
View/download PDF

2. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)

Author

Masaru Suzuki, Satoshi Oizumi, Eiki Kikuchi, Kenya Kanazawa, Hisashi Tanaka, Kaoruko Shimizu, Hiroshi Yokouchi, Ryoichi Honda, Toshiyuki Harada, Hajime Asahina, Tomoo Ikari, Kei Takamura, Tetsuya Kojima, Masao Harada, Yuka Fujita, Hiroshi Isobe, Hirotoshi Dosaka-Akita, Takahiro Ogi, Masaharu Nishimura, Fumiko Sugaya, and Satoshi Konno

Subjects
Male, 0301 basic medicine, Pulmonary and Respiratory Medicine, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Paclitaxel, medicine.medical_treatment, Phases of clinical research, Interstitial lung disease, Nab-paclitaxel, Gastroenterology, Carboplatin, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Non-small cell lung cancer, Albumins, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Prospective Studies, Lung cancer, Aged, Pneumonitis, Chemotherapy, business.industry, Middle Aged, medicine.disease, Survival Rate, Clinical trial, 030104 developmental biology, Oncology, chemistry, 030220 oncology & carcinogenesis, Concomitant, Adenocarcinoma, Female, Lung Diseases, Interstitial, business
Abstract

Objectives Patients with concomitant advanced non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD) are excluded from most clinical chemotherapy trials because of the high risk of exacerbating the latter condition. This study prospectively investigated the efficacy and safety of albumin-bound paclitaxel (nab-paclitaxel) in combination with carboplatin in patients with both advanced NSCLC and ILD. Patients and methods The enrolled patients had treatment-naive, advanced NSCLC with ILD. Patients received 100 mg/m2 nab-paclitaxel weekly and carboplatin at an area under the concentration-time curve of 6 once every 3 weeks for 4–6 cycles. The primary endpoint was the overall response rate (ORR); secondary endpoints included toxicity, progression-free survival (PFS), and overall survival (OS). Results Thirty-six patients were enrolled between April 2014 and September 2017. Sixteen patients (44.4%) had adenocarcinoma, 15 (41.7%) had squamous cell carcinoma (Sq), and 5 (13.9%) had non-small cell carcinoma. The median number of cycles administered were 4 (range: 1–6). The ORR was 55.6% (95% confidence interval [CI]: 39.6–70.5). The median PFS and OS were 5.3 months (95% CI: 3.9–8.2) and 15.4 months (95% CI: 9.4–18.7), respectively. A greater proportion of patients with Sq experienced improvements than did those with non-Sq: ORRs, 66.7% (95% CI: 41.7–84.8) vs. 47.6% (95% CI: 28.3–67.6) (P = 0.254); median PFS, 8.2 months (95% CI: 4.0–10.2) vs. 4.1 months (95% CI: 3.3–5.4) (HR, 0.60 [95% CI, 0.30–1.20]; P = 0.15); and median OS, 16.8 months (95% CI: 9.8–not reached) vs. 11.9 months (95% CI: 7.3–17.4) (HR, 0.56 [95% CI, 0.24–1.28]; P = 0.17). Two patients (5.6%) experienced grade ≥2 pneumonitis and 1 patient (2.8%) died. Conclusion Weekly nab-paclitaxel combined with carboplatin showed favorable efficacy with acceptable toxicity in patients with both advanced NSCLC and ILD.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results